LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Regeneron Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

593 1.83

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

577.46

Massimo

593.57

Metriche Chiave

By Trading Economics

Entrata

-109M

809M

Vendite

-761M

3B

P/E

Media del settore

14.64

56.602

EPS

8.22

Rendimento da dividendi

0.67

Margine di Profitto

26.701

Dipendenti

15,158

EBITDA

-54M

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+40.88% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.67%

2.45%

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-13B

62B

Apertura precedente

591.17

Chiusura precedente

593

Notizie sul Sentiment di mercato

By Acuity

36%

64%

122 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2025, 11:07 UTC

Utili

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 feb 2025, 12:13 UTC

Utili

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

29 apr 2025, 18:04 UTC

Discorsi di Mercato
Utili

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 apr 2025, 14:39 UTC

Discorsi di Mercato
Utili

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 apr 2025, 14:29 UTC

Utili

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 13:11 UTC

Utili

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 10:32 UTC

Utili

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Rev $3.03B >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Net $808.7M >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q EPS $7.27 >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 apr 2025, 10:51 UTC

Notizie principali

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Notizie principali

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Utili

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Utili

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Utili

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Utili

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Utili

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Utili

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Utili

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Utili

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb 2025, 11:32 UTC

Utili

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb 2025, 11:31 UTC

Utili

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 gen 2025, 08:30 UTC

Acquisizioni, Fusioni, Takeovers

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 gen 2025, 10:30 UTC

Notizie principali

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 ott 2024, 13:58 UTC

Utili

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 ott 2024, 10:52 UTC

Utili

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 ott 2024, 10:34 UTC

Utili

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 ott 2024, 10:33 UTC

Utili

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 ott 2024, 10:33 UTC

Utili

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

Confronto tra pari

Modifica del prezzo

Regeneron Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.88% in crescita

Previsioni per 12 mesi

Media 804.95 USD  40.88%

Alto 979 USD

Basso 535 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

18

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

542.44 / 599.76Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

122 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.